Advertisement ADVANCELL - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More


Advanced Nanomedicine for Oncology, Dermatology and Neurology Indications

July 12, 2011

Biotech Companies Advancell, Neurotec Pharma and Aromics, Have Created the Consortium MSALS – in Order to Develop a New Treatment for Multiple Sclerosis

MSALS is funded through ACC1Ó’s Technological Innovation Nucleos programme, which provides assistance to projects being developed by groups of companies...
pharmacuetical business review
July 12, 2011

Advancell Announces Promising Phase I/IIa Results with Acadra® in CLL

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a Phase I/IIa clinical study conducted with Acadra® in Chronic...
pharmacuetical business review



ADVANCELL is a Spanish biotechnology company focused on the development of drug candidates with significant commercial potential in oncology, dermatology and neurology indications.

The company creates new product opportunities by leveraging an innovative nanosystems technology and by in-licensing promising projects at a pre-clinical stage.

ADVANCELL is also open to approaches from parties interested in collaboration.

Clinical development for drug candidates

ADVANCELL has several programmes in clinical development and pursues a series of preclinical opportunities, both proprietary and in collaboration.

The company’s headquarters are located in the Barcelona Science Park (PCB), while its nanosystems laboratory is in Santiago de Compostela, Spain.

Reformulating drug candidates

ADVANCELL has developed the proprietary and patent-protected Dermosome Technology® to formulate and reformulate drug candidates that have been identified internally or in collaboration with its partners.

The company’s technology utilises polysaccharides and other excipients to generate nanosystems that confer new properties the active ingredient, creating nanomedicines that will result in benefits to patients such as increased efficacy, better safety, or more convenient dosing.

Small molecule drug formulation

Based on the properties of its technology, ADVANCELL’s nanosystems are suitable for formulating small molecule drugs, proteins, peptides, antibodies or antibody fragments and nucleic acids for dermal or mucosal delivery.


Baldiri Reixac 10-12
08028- Barcelona

Phone: +34 934 034 545
Fax: +34 934 034 544

Dermal Application

ADVANCELL's Dermosome Technology® provides topical administration of lipophilic compounds. This technology is made up of an oily core that is covered by a polysaccharide layer and other components of the formulation. Dermosome Technology adheres to the skin, allowing for a longer time of contact. Together with its sub-micrometric size, this increases the surface area of…

Nasal Application

ADVANCELL's technology has potential applications for the nasal administration of bioactive molecules such as vaccines, peptides or genetic material, as has been described in multiple scientific papers published by a research team led by professor María José Alonso of the University of Santiago de Compostela. Several in-vivo studies have shown that the therapeutic effects or…

Oral Application

Due to its unique and characteristic properties, ADVANCELL's nanosystems can be used for the oral administration of drugs. With this technology, the active molecule administered is protected inside nanosystems as they are stable against breakdown by the gastric fluids. In addition, their mucoadhesive properties enhance the time of adhesion to the intestine walls, thus facilitating…

Platform Technology

Research and development (R&D) activities at ADVANCELL are very focused on generating new high-potential product candidates by creating new nanomedicines by leveraging its innovative technology. ADVANCELL's technology enables new and improved formulations of existing active principles by encapsulating them in nanosystems based on its technology, to improve delivery of drugs to the appropriate site and…

Pre-clinical R&D Pipeline

ADVANCELL generates proprietary drug candidates by leveraging an innovative nanosystems drug delivery technology to reformulate and reposition existing drugs. The company focuses on oncological and dermatological indications. Projects in these areas continue to reach the evaluation and feasibility stage. In addition, other indications with significant market potential and considerable unmet medical need are also being…
Quick Contact ADVANCELL
Quick Contact ADVANCELL
Quick Contact ADVANCELL

Quick Contact ADVANCELL
Quick Contact ADVANCELL
Quick Contact ADVANCELL


Optional Data

Almost there, complete this form and hit the submit button to complete your registration.


Finally, complete a quick security check and confirm terms and conditions:

Quick Contact ADVANCELL